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Type A neurotoxin (NTX) of Clostridium botulinum was puriﬁed by a simple procedure using a lactose gel column. The toxicity of
this puriﬁed toxin preparation was retained for at least 1 year at −30◦C by supplementation with either 0.1% albumin or 0.05%
albuminplus1%trehalose.WhenpuriﬁedNTXwasusedtotreat49patientswithurinaryincontinencecausedbyeitherrefractory
idiopathic or neurogenic detrusor overactivity, 36 patients showed signiﬁcant improvement in symptoms. These beneﬁcial eﬀects
were also observed in cases of prostatic hyperplasia. The results obtained with NTX were similar to that of Botox. The eﬀects of
NTX on trigeminal neuralgia induced by infraorbital nerve constriction (IoNC) in rats were also studied. Trigeminal ganglion
neurons from ipsilateral to IoNC exhibited signiﬁcantly faster onset of FM4-64 release than sham-operated contralateral neurons.
Intradermal injection of NTX in the area of IoNC alleviated IoNC-induced pain behavior and reduced the exaggerated FM4-64
release in trigeminal ganglion neurons.
1.Introduction
In this manuscript, three main topics are described: (1) the
structure of type A progenitor toxin and puriﬁcation of type
A neurotoxin by a lactose gel column based on progenitor
toxin characteristics; (2) treatment of patients with urinary
incontinence and prostate hyperplasia with this puriﬁed
neurotoxin; (3) application of the puriﬁed neurotoxin for
treating trigeminal neuralgia in a rat model. Introduction
including the purpose of these three topics is described at the
beginning of each paragraph.
2 .S truc tur eo fT ypeAP r og e nit o rT o xinand
Puriﬁcationof TypeA Neurotoxin
Clostridium botulinum strains produce immunologically dis-
tinctneurotoxins(NTX;typesAtoG)withmolecularmasses
(Mr) of approximately 150kDa. In an activated form, the
NTXs have a cleavage site at the one third position of their N
terminus conjugated with an S–S bond, which can be cleaved
by cellular proteases or exogenously added trypsin. In
culture ﬂuid and in acidic foods, the NTXs associate with
nontoxic components and form large complexes designated2 Journal of Toxicology
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Figure 1: Progenitor L toxin structure. (a) Scheme indicating that (1) under alkaline conditions PTXs dissociate into an NTX and nontoxic
components; (2) fully activated NTX is cleaved at a site in the N-terminus; (3) HA1 and HA3b bind galactose and sialic acid, respectively.
(b) Predicted tertiary structure of type C and D L toxins and molar ratio of their (sub)components. Model is based on the structural data of
Hasegawa et al. [8]a n dN a k a m u r ae ta l .[ 7]. Three dimensional structure of HA1 and its binding sites for sugars are also shown. Both type
A and C HA1 showed similar structures consisting of two β-trefoil domains conjugated by an α-helix. Two sugar-binding sites (I and II) on
C-terminal β-trefoil domain are predicted and A-HA1 and C-HA1 binds to galactose via sites II and I, respectively. In the case of type C,
HA1 also bound to sialic acid via site I [6].
progenitor toxins (PTXs). PTXs are found in three forms
with Mr of 900kDa (19S, LL), 500kDa (16S, L), and 300kDa
(12S,M);later,itbecameclearthattheactualMr oftheLand
LL toxins is much larger than 500 and 900kDa, respectively
(see below). The M toxin is composed of an NTX and a
nontoxic component having no hemagglutinin (HA) activity
(designated nontoxic non-HA; NTNH), whereas the L and
LL toxins are composed of an NTX(s), an NTNH(s), and
HAs. The type A strain produces three forms of toxin (M, L,
and LL), while types B, C, and D produce M and L toxins.
In alkaline conditions in the absence of gastric juices, the
PTXs dissociate into the NTX(s) and nontoxic components,
L and LL toxins (designated HA-positive PTXs) dissociate
into an NTX(s), and a nontoxic component (complex) of an
NTNH(s) and HAs, and the M toxin dissociates into an NTX
and an NTNH [1].
We found that (1) LL toxin is a dimer of L toxins; (2)
cleavage or deletion is detected in the N-terminal region of
the M toxin NTNH; (3) HA consists of three to four
subcomponents designated HA-1, -2, and -3 (-3a, -3b);
(4) HA1 and HA3b bind to galactose and sialic acid,
respectively, present on the surface of erythrocytes and small
intestine epithelial cells [2–4]. Recently, we also analyzed
the crystal structures of type A and C HA1, and type
C HA3 to describe their sugar binding sites [5–7]. Fur-
thermore, by investigating the tertiary structure of type
C and D L toxins with electron microscopy, the molar
ratio of NTX:NTNH:(HA1:HA2:HA3) was predicted to
be1:1:(2:1:1) x3, and the actual L toxin Mr was calculated
tobeapproximately750kDa.TheLLtoxinMr was,therefore,
estimated to be about 1,500kDa because it is a dimer of the
L toxin, although its tertiary structureremains unclear [7, 8].
Some of these data are summarized in Figure 1.
Type A and B PTXs have been used to treat patients with
strabismus, blepharospasm, nystagmus, facial spasm, spastic
aphonia, and many other dystonias including cervical dysto-
nia, hemicrania (migraine), and some urinary disorders [9–
16].Forthesetreatments,PTXsaremainlyusedbecausethey
are easily obtained and are more stable than NTXs. While
these treatments are very eﬀective, they can present serious
problems in some patients in that anti-PTX, including
anti-NTX, antibodies are sometimes produced after several
injections. We think that the use of NTX alone may be better
than using PTX because both HA1 and HA3b of PTX have
immunoenhancing activity, although there are no deﬁnitive
data for this immunoreactivity in humans [17]. Therefore,Journal of Toxicology 3
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Figure 2: Simple procedure for purifying type A and B NTXs. Partially puriﬁed type A HA-positive PTXs (L and LL) or trypsin-treated
(fully activated) type B L toxin was layered on a lactose gel column under acidic conditions (pH 6.0). After washing, the pH was adjusted to
8.0 to obtain the NTX. The bound HA-positive PTX(s) and nontoxic components were eluted with buﬀer supplemented with 0.2M lactose.
we established simple procedures for purifying type A NTX
and for long-term storage of type A NTX at −30◦C without
reductions in toxicity.
As shown in Figure 1, the HA-positive PTXs bind
to galactose via HA1 under acidic conditions, and the
conjugation of NTX and nontoxic components dissociates
under alkaline conditions. Therefore, to isolate only the HA-
positive PTXs, partially puriﬁed PTXs were ﬁrst subjected
to an aminophenyl beta-lactose gel column equilibrated
with 10mM sodium phosphate buﬀer (pH 6.0). From this
column,puriﬁedpreparationsofHA-positivePTXs,NTX,or
HA plus NTNH could be obtained by washing the column
with diﬀerent buﬀers (Figure 2). This procedure is simpler
than previous protocols that used several diﬀerent columns
and conditions. Moreover, the NTX preparation puriﬁed by
alactosegelcolumnshowedthesametoxicitypermgprotein
and SDS-PAGE banding proﬁle as those obtained with
previous procedures. We also found that NTX toxicity can be
fully maintained for at least one year when albumin (0.05%),
trehalose (1%), and Tween-20 (0.01%) were added to the
storage solution [18]. The NTX, albumin, and trehalose were
diluted in endotoxin-free isotonic sodium chloride solution.
Finally, this puriﬁed type A NTX preparation was used as
a therapeutic agent for urinary incontinence and prostate
hyperplasia and as an analgesic for trigeminal neuralgia in
ar a tm o d e l .
Prior to clinical use, the safety and quality of the
NTX preparation and albumin were checked using NTX
concentrations that were 100 folds greater than those used in
treatmentandalbuminat50mg/mL.Cytotoxicity wasevalu-
ated using IMR-32 (human, abdominal), Neuro-2a (mouse,
spinal cord), U937 (human, pleural eﬀusion), NOMO-1
(human, peripheral blood), HT-29 (human, colon), Caco-2
(human, colon), HeLa (human, cervix), and Vero (African
green monkey, kidney) cell lines. A mutagenicity assay of
NTX and albumin was performed by an Ames test according
to the preincubation technique of Yahagi et al. [19]. Prion
and endotoxin contamination was assayed with a Prionics-
Check Western kit (Prionics AG) and a Limulus amoebocyte
lysate assay (BioWhittaker), respectively, and that of AIDS
and hepatitis viruses was assayed by PCR by a commercial
company (SRL, Tachikawa, Japan). In addition, approval
from the ethics committees of both Okayama University and
Kawasaki Medical School for this clinical trial and patient
informed consent were obtained.
3.ClinicalTrials
3.1. Refractory Urgency Incontinence. A preliminary study by
Schurch and colleagues on 31 patients with neurogenic
detrusor overactivity (NDO) demonstrated a signiﬁcant
increase in the mean maximum bladder capacity (296 to
480mL, P<0.016) and a signiﬁcant decrease in mean
maximum detrusor voiding pressure (65 to 35cmH2O, P<
0.016) in patients injected with Botox (the main toxin used
was likely LL) [14]. Seventeen of 19 patients were completely
continent and very satisﬁed with the procedure. Interest-
ingly, baseline improvement of urodynamic parameters and
incontinence persisted in 11 patients after a 36-week follow-
up period. Cruz and associates recently reported the results
of a multicenter, international, randomized, double-blind,4 Journal of Toxicology
and placebo-controlled phase III clinical trials of Botox for
NDO patients. Patients received 30 intradetrusor injections
of either 200U (n = 92) or 300U (n = 91) Botox, or placebo
(n = 92).Byweek6,either200Uor300UBotoxsigniﬁcantly
reduced the number of incontinence episodes per week
(−21.8 and −19.4, resp.), signiﬁcantly increased maximal
cystometric capacity, and signiﬁcantly improved quality of
life scores compared to placebo. The median time to patient
request for retreatment was the same for both Botox doses
(42.1 weeks) [20].
Intradetrusor Botox injections have extended beyond the
realm of neurogenic bladders to patients with nonneuro-
genic voiding and storage disorders [14, 15]. Dmochowski
and associates obtained favorable eﬀects with intradetrusor
Botox injections in a double-blind, placebo controlled,
randomized study that evaluated several Botox doses (i.e.,
50, 100, 150, 200, and 300U) versus placebo in 313 patients
with idiopathic detrusor overactivity (IDO) [16]. Patients
who experienced urinary urge incontinence with at least
eightepisodes/weekandeightormoremicturitions/daywere
included in the study. The primary endpoint was weekly
urinary urgency incontinence episodes at 12 weeks. The
authors observed a signiﬁcant diﬀerence in the number of
urgency incontinence episodes/week at many time points for
Botox -treated patients compared to placebo patients.
Our group performed a clinical trial using NTX to
treat patients with urgency incontinence caused by NDO
or by IDO. A total of 200U (for NDO), 100U (IDO for
women), and 50U (IDO for men) NTX were injected
into the bladder wall in a minimally invasive outpatient
technique using ﬂexible cystoscopy. All patients with NDO
performed clean intermittent catheterization before the
treatment. Urodynamic maximum cystometric capacity and
maximum detrusor pressure were evaluated before and
one month after treatment by ﬁlling cystometry. Subjective
and objective measures included frequency of voids and
number of incontinence episodes per 24 hours from a 3-
day bladder diary before treatment and 1, 3, and 6 months
after treatment. A total of 16 patients with spinal NDO and a
meanageof42.3years(range20to75years,2femalesand14
males) and 33 with IDO and a mean age of 71.9 years (range
50 to 83 years, 15 females and 18 males) were treated [18].
NTX treatment produced an increase in the mean maximal
cystometric capacity from 138.2 ± 13.8mL at baseline to
358.8 ± 25.2mL at one month (P = 0.0036) in NDO
patients and 171.8 ± 10.2mL at baseline to 319.8 ± 19.4mL
at one month (P<0.0001) in IDO patients. The mean
maximaldetrusorpressureindetrusoroveractivitydecreased
from 65.9 ± 6.5cmH 2O at baseline to 27.3 ± 4.8cmH 2O
(P = 0.0025) one month after treatment in NDO patients
and 63.5 ± 5.0cmH 2O at baseline to 32.3 ± 4.4cmH 2O
(P = 0.0001) at one month for IDO patients. The mean
number of daily urinary incontinence episodes decreased
from 4.67 ± 0.7t o1 .07 ± 1.0( P<0.0001) at 1 month and
to 2.07 ± 0.4( P = 0.0002) at 3 months for NDO patients.
The mean number of episodes of urinary incontinence daily
decreased from 4.46 ± 0.5t o1 .49 ± 0.4( P<0.0001) at 1
month, to 1.82 ± 0.4( P = 0.0002) at 3 months, and to
2.28 ± 0.7( P = 0.0051) at 6 months for IDO patients. Ten
of 16 NDO patients (62.5%) and 15 of 33 IND patients
(45.5%) obtained complete continence within 1 month of
NTXinjection.NTXtreatmenthalvedthenumberofurinary
incontinence episodes for thirteen NDO patients (81%) and
23 (69.7%) IDO patients. The mean duration of eﬃcacy was
3 to 10 months (median 4 months) in NDO patients and 4
to 12 months (median 6 months) in IDO patients. Ten of
33 (30.3%) IDO patients had no subjective improvement.
Although 5 patients had improved cystometric ﬁndings, they
did not have subjective improvement due to the increase
of residual urine volume and voiding dysfunction. Nineteen
(57.5%) of 33 IDO patients had residual urine volumes
>100mL at 1 month posttreatment and 4 male patients
required clean intermittent catheterization for a few weeks.
N os e r i o u ss i d ee ﬀects occurred (Table 1).
In our study, NTX injection therapy achieved excellent
results within one month of injection. Of the 49 patients
analyzed, 36 patients reported a decrease or absence of
incontinence. Followup analysis of these patients showed
that these eﬀects lasted 3 to 12 months after the single
treatment. While the optimum injection dose has not yet
been determined, in our study, 50–100U for IDO and 200U
for NDO were supposed to be suitable treatment doses.
These results demonstrated that NTX has almost the same
activity as Botox.
3.2. Benign Prostatic Hyperplasia. The ﬁrst oﬀ-label use of
Botoxtotreatbenignprostatichyperplasia(BPH)inhumans
was reported by Maria et al. in 2003 [21]. In a randomized,
placebo-controlled study, 30 men with symptomatic BPH
were randomized to receive either saline or 200U Botox,
which produced clinical improvement within 1 month of
treatment. By 2 months, 13 patients in the treatment
group (87%) versus 3 patients in the control group (10%)
reported subjective relief of BPH symptoms (P = 0.00001).
At 12 months, the International Prostate Symptom Score
decreased by 62% for the Botox-treated group, maximum
urinary ﬂow rate increased by 85%, postvoid residual urine
volumedecreasedby85%,andprostaticvolumedecreasedby
61%. The prostatic-speciﬁc antigen values were also reduced
by 38%. No urinary incontinence or systemic side eﬀects
were reported. In other reports of Botox treatment for
prostatic hyperplasia, the increase in maximum urinary ﬂow
rate (40–121%) and the decrease in International Prostate
Symptom Score (48–65.5%) were statistically signiﬁcant
[11–13]. There was a statistically signiﬁcant reduction in
prostatic volume that varied from 13.3% to 68%.
We treated 10 male patients (mean age 70.0 years,
range 61–79 years) with unsatisfactory response to alpha1-
adrenoceptorblockerswith200U(prostatevolume>30mL)
or 100U (prostate volume < 30mL) NTX injected into the
prostate using a minimally invasive outpatient technique.
Evaluation included uroﬂowmetry, postvoid residual urine
volume, prostate volume, and International Prostate Symp-
tom Score and was carried out at baseline and 1, 3, 6,
and 12 months posttreatment. Prostate-speciﬁc antigen was
measured at baseline, 6 months, and 12 months after injec-
tion. Seven out of 10 patients noted improvement withinJournal of Toxicology 5
Table 1: Change of parameters before and after intradetrusor NTX treatment of NDO and IDO patients.
Baseline 1 month 3 months 6 months
NDO
MCC (mL) 138.2 ± 13.8 358.8 ± 25.2∗ ——
Pdetmax (cmH2O) 65.9 ± 6.5∗ 27.3 ± 4.8∗ ——
Frequency 7.53 ± 0.7∗ 5.71 ± 0.3∗ 6.31 ± 0.4∗ —
Incontinence (times/day) 4.67 ± 0.7∗ 1.07 ± 1.0∗ 2.07 ± 0.4∗ —
IDO
MCC (mL) 171.8 ± 10.2 319.8 ± 19.4∗ ——
Pdetmax (cmH2O) 63.5 ± 5.0∗ 32.3 ± 4.4∗ ——
Frequency 13.7 ± 0.6∗ 11.4 ± 0.7∗ 11.2 ± 0.7∗ 10.5 ± 0.9∗
Incontinence (times/day) 4.46 ± 0.5∗ 1.49 ± 0.4∗ 1.82 ± 0.4∗ 2.28 ± 0.7∗
∗Compared with baseline, P<0.05.
MCC: maximum cystometric capacity; Pdetmax: maximum detrusor pressure at detrusor overactivity.
Table 2: BPH Patient proﬁles and results after intraprostatic NTX treatment.
Baseline 1 week 1 month 3 months 6 months 9 months 12 months
Number of patients 10 10 10 10 9 9 8
IPSS 23.8 ± 7.0 19.4 ± 9.3∗ 16.3 ± 10.3∗ 14.9 ± 8.2∗ 13.8 ± 7.5∗ 13.8 ± 7.6∗ 16.9 ± 7.3∗
Storage 8.7 ± 4.8 7.2 ± 4.5 6.7 ± 5.4 5.3 ± 3.8∗ 4.4 ± 3.5∗ 5.4 ± 3.5∗ 5.2 ± 4.3∗
Voiding 11.8 ± 3.4 9.5 ± 4.4 6.9 ± 5.0∗ 7.4 ± 4.8∗ 7.0 ± 4.2∗ 6.8 ± 4.5∗ 7.4 ± 4.6∗
QOL score 5.2 ± 1.0 4.3 ± 1.6∗ 3.4 ± 1.6∗ 3.3 ± 1.8∗ 3.2 ± 1.6∗ 3.7 ± 1.4∗ 4.3 ± 1.5∗
Qmax, mL/s 6.3 ± 3.1 5.5 ± 2.0 6.1 ± 2.6 8.8 ± 2.9∗ 6.8 ± 3.9 6.2 ± 2.2 7.2 ± 4.0
Residual urine (mL) 99.5 ± 94.5 84.9 ± 83.1 101.5 ± 97.0 65.3 ± 73.6∗ 52.9 ± 62.5∗ 86.3 ± 100 72.4 ± 58.2
Prostatic volume
(mL) 47.8 ± 21.2 45.9 ± 22.3 40.2 ± 18.2∗ 39.2 ± 19.5∗ 40.2 ± 19.2∗ 42.9 ± 23.2 41.0 ± 17.0
PSA (ng/mL) 4.30 ± 3.0 3.75 ± 2.2 4.35 ± 2.8
∗Compared with baseline, P<0.05.
1 month. The mean International Prostate Symptom Score
decreased from 23.8 ± 7.0t o1 6 .3 ± 10.3( P = 0.0093) at
1 month, to 14.9 ± 8.2( P = 0.0074) at 3 months, and
to 16.9 ± 7.3( P = 0.018) at 12 months after injection.
The mean prostate volume decreased from 47.8 ± 21.2t o
39.2 ± 19.5mL(P = 0.0076) at 3 months. Postvoid residual
urine volume improved at 3 and 6 months posttreatment.
The mean prostate-speciﬁc antigen did not change during
the observation period (Table 2).
Although our study achieved only an 18% reduction in
prostate volume, this outcome was similar to that obtained
by Kuo and Chuang et al. [11, 12]. Botox eﬀects appeared
during the ﬁrst week to one month after treatment and
these beneﬁts were maintained for 6 to 12 months [11–
13]. In our study, the beneﬁcial results were evident within
1 week of treatment and continued for 12 months. The
maximum eﬀects were from 3 to 9 months and the prostatic
volume reached a minimum level at 3 to 6 months. Silva
et al. [13] also reported that the prostate volume decreased
gradually to a minimum level at 6 months. Therapeutic
eﬃcacy relates to the injection dosage, diﬀusion of toxin
within the prostate, the ratio of epithelium and stromal
components, and detrusor function. The improvements in
International Prostate Symptom Score, maximum urinary
ﬂ o wr a t e ,r e d u c t i o no fp r o s t a t ev o l u m e ,a n dd u r a t i o no f
eﬀect seen for our cases were almost the same as previous
reports for Botox [11–13].
4. Application of NTX in a Rat Model of
Trigeminal Neuropathy
Trigeminal neuropathic pain is characterized by recur-
rent episodes of intense, lancinating facial pain [22, 23].
Management of trigeminal neuropathic pain remains a
major therapeutic challenge with antiepileptic drugs cur-
rently being the main treatment choice [24, 25]. However,
since some patients cannot tolerate these drugs because
of side eﬀects (e.g., dizziness, drowsiness), more eﬀective
and safer drugs are required to treat trigeminal neuro-
pathic pain. Botulinum toxin is one such candidate, and
open-label trials with trigeminal neuralgia patients showed
botulinum toxin eﬃcacy [26, 27]. Animal studies reported
that botulinum toxin injection into the peripheral tissue
decreases leg neuropathic pain induced by sciatic nerve
ligation or transduction [28–30] .H o w e v e r ,as y s t e m a t i c
review indicated that there is a lack of suﬃcient data that
would suitably recommend botulinum toxin as an evidence-
based treatment for secondary headaches or cranial neu-
ralgias [31]. Most of these clinical trials used commercially
available botulinum PTXs and did not use NTX. Since the
true eﬀects of NTX are currently unclear, continued studies
on the eﬀect of NTX treatment for trigeminal neuropathic
pain animal models are needed. Here, we evaluated the
eﬀect of type A NTX in trigeminal neuropathic pain animal
models.6 Journal of Toxicology
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Figure 3: Mechanical allodynia after injection with type A NTX or PTXs in a rat hindpaw neuropathy model. Mechanical allodynia was
tested with an electric von Frey ﬁlament and the hindpaw withdrawal thresholds measured. The data were divided by the contralateral na¨ ıve
hindpaw data. After sciatic nerve contraction, the ipsilateral hindpaw threshold was decreased. Ipsilateral injection with NTX or HA-positive
PTXs produced the same toxicity (10U/0.1mL) in mechanical allodynia. The eﬀects of NTX on decreasing pain levels were longer lasting
than HA-positive PTXs. n = 4; data represent the mean ± SEM.
Kitamura et al. [32]reportedthatalargedecreaseinhead
withdrawal threshold was observed after ipsilateral infraor-
bital nerve (branch of trigeminal nerve) constriction (IoNC)
by stimulating the face with an electric von Frey ﬁlament.
This result showed that the rats had tactile allodynia,
which trigeminal neuropathic pain patients usually show
clinically and which is considered to be a pain response. The
intradermal ipsilateral injection of type A NTX (100pg or
10U) signiﬁcantly increased the head withdrawal threshold
compared to saline-injected trigeminal neuropathic pain
rats, suggesting that NTX injection decreased rat trigeminal
neuropathic pain. These results are consistent with those of
Filipovi´ c et al. [33], who also found thatunilateral injection
of Botox reduced IoNC-induced allodynia with the eﬀect
lasting more than 2 weeks. Next, we compared the analgesic
eﬀect of type A NTX and HA-positive PTXs (a mixture of L
and LL toxins obtained using a lactose gel column as shown
in Figure 2). Figure 3 shows that, compared to PTX, NTX
decreased pain levels for longer periods.
Kumada et al. [34] tested freely moving rats and found
that type A NTX attenuated IoNC-induced thermal hyper-
algesia. These eﬀects were dose dependent (2–200pg) and
statistically signiﬁcant at 100 and 200pg (P<0.05). Oﬀ-
site (neck) injection of type A NTX did not relieve thermal
hyperalgesia and coinjection of type A NTX with a neu-
tralizing antibody in the area of infraorbital nerve innerva-
tion prevented relief of thermal hyperalgesia. These results
strongly suggest that intradermal injection of type A NTX
in the area of infraorbital nerve innervation alleviates IoNC-
induced thermal hyperalgesia.
The detailed mechanisms of the type A NTX eﬀects on
trigeminal neuropathic pain in animal models are not clear.
Some studies suggest that the botulinum toxin undergoes
axonal transport. Antonucci et al. [35] reported that,
after injection of type A NTX into rat whisker muscles,
cleaved synaptosomal-associated protein of 25kDa (SNAP-
25) appeared in the facial nucleus, indicating that the toxin
migrated along the axons and underwent neuronal transcy-
tosis. Matak et al. [36] found that Botox truncated SNAP-25
in the medullary dorsal horn (spinal trigeminal nucleus) was
evident 3 days following the peripheral treatment. Filipovi´ c
et al. [33] reported that unilateral Botox injection reduced-
IoNC induced bilateral dural extravasation while Kitamura
et al. [32] observed that neurons isolated from trigemi-
nal ganglion ipsilateral to infraorbital nerve constriction
exhibited signiﬁcantly faster onset of FM4-64 dye release
in dissociated trigeminal ganglion neurons compared to
neurons in contralateral sham surgery. Intradermal injection
of type A NTX in the area of infraorbital nerve innervation
reduced the exaggerated FM4-64 dye release in trigeminal
ganglion neurons from these rats.
In this manuscript, we demonstrated that type A NTX
puriﬁed with a lactose gel column could be used clinically
andwasaseﬀectiveascommerciallyavailablePTXs.Recently,
preparations of type A NTX alone and type B PTX (probably
L toxin) have been made commercially available. The
production of anti-NTX Ab in repeatedly injected patients as
well as the eﬃcacy of the toxin must be monitored. Usually,
type B toxin is not fully activated but can be activated
following trypsin treatment. Our procedure is suitable for
purifying fully activated type B toxin with partially puriﬁed
type B PTXs ﬁrst fully activated by trypsin just prior to
loading on the lactose gel column. After binding of the L
toxin to the column, trypsin was washed out and the fully
activated L toxin or NTX can then be obtained similarly
to type A toxins (Figure 2)[ 37]. We also found that theJournal of Toxicology 7
toxicity of type B NTX could be maintained at −30◦Cf o r
long periods by adding 0.05% albumin. We plan to evaluate
fully activated type B NTX for clinical usage in the future.
Abbreviations
NTX: Neurotoxin
PTX: Progenitor toxin
HA: Hemagglutinin
NTNH: Nontoxic non-HA
NDO: Neurogenic detrusor overactivity
IDO: Idiopathic detrusor overactivity
IoNC: Infraorbital nerve constriction.
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